In the ccRCC cohort, the mean number of prior lines of therapy was 2.5 (SD = 1.8), four patients having had prior ICIs, eight having received VEGF inhibitors, and three having received MET inhibitors. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.